Cleveland Clinic Children's Outcomes
Pediatric Transplant Program
Pediatric Blood & Marrow Transplant
To avoid central line associated bloodstream infections (CLABSIs), healthcare providers must follow a strict protocol when inserting the line and stringent infection control practices each time they check the line or change the dressing.¹ The Pediatric Blood and Marrow Transplant program's CLABSI rate falls below the national benchmark set forth by the National Healthcare Safety Network.
Non-Mucosal Barrier Central Line-Associated Bloodstream Infections
2016 - 2017
CL = central line, NHSN = National Healthcare Safety Network
ᵃNational Healthcare Safety Network 2016–2017 benchmark for central line-associated bloodstream infections (CLABSI) is 2.4/1000 central line days for pediatric hematopoietic stem cell transplant ward.
Blood & Marrow Transplant Survival
2014 - 2017
Working closely with the Taussig Cancer Institute and the Adult Blood and Marrow Transplant (BMT) program, Cleveland Clinic Children's Pediatric BMT Program provides lifesaving procedures that offer hope for curing a variety of malignant and nonmalignant diseases, immunologic diseases, and metabolic disorders that were once thought to be incurable. The pediatric program has earned accreditation from the Foundation for the Accreditation of Cellular Therapy, which establishes standards for high-quality medical and laboratory practice in cellular therapies. Despite the high-risk patient population, the program provides outstanding care with a consistently low transplant-related mortality rate and high overall survival.
|Outcomes¹||Malignant (N = 1548)||Non-Malignant (N = 1578)|
|100 Day Survival||94 (93 - 96)%||96 (95 - 97)%|
|1 Year||79 (77 - 81)%||90 (89 - 92)%|
¹Comparison data was published with the prior approval of the Center for International Blood and Marrow Transplant Research (CIBMTR).
ᵃNot all patients in 2017 are 1 year from transplant.